Getting beyond the immunotherapy divide: a call to action

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
John H. Stewart
Associate director for clinical research, University of Illinois Cancer Center
Robert A. Winn
Director, University of Illinois Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
John H. Stewart
Associate director for clinical research, University of Illinois Cancer Center
Robert A. Winn
Director, University of Illinois Cancer Center

Login